Check-Cap Ltd. (NASDAQ: CHEK) Stock Competitors & Peer Comparison
See CHEK's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for CHEK and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CHEK | $1.86 | +1.64% | 10.9M | -0.43 | -$4.30 | N/A |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.66% |
| TMO | $694.76 | +2.63% | 257.5B | 30.00 | $23.16 | +0.27% |
| DHR | $230.25 | +1.73% | 161.9B | 28.86 | $7.98 | +0.66% |
| IDXX | $676.04 | +0.79% | 53.3B | 47.54 | $14.22 | N/A |
| A | $174.76 | +1.73% | 49.3B | 30.08 | $5.81 | +0.59% |
| WAT | $457.60 | +1.00% | 44.9B | 33.45 | $13.68 | N/A |
| IQV | $271.83 | +2.62% | 44.8B | 22.40 | $12.13 | N/A |
| NTRA | $310.67 | -14.59% | 44.7B | -235.14 | -$1.32 | N/A |
| MTD | $1,722.15 | +2.57% | 34.5B | 39.56 | $43.51 | N/A |
Stock Comparison
Danaher Corporation (NYSE: DHR-PB)
CHEK vs DHR-PB Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, CHEK's ROE is -2.26%, compared to DHR-PB's ROE of +0.08%. Regarding short-term risk, CHEK is more volatile compared to DHR-PB. This indicates higher risk in terms of short-term price fluctuations for CHEK.Check DHR-PB's competition here
Thermo Fisher Scientific Inc. (NYSE: TMO)
CHEK vs TMO Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, TMO has a market cap of 257.5B. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while TMO trades at $694.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas TMO's P/E ratio is 30.00. In terms of profitability, CHEK's ROE is -2.26%, compared to TMO's ROE of +0.13%. Regarding short-term risk, CHEK is less volatile compared to TMO. This indicates lower risk in terms of short-term price fluctuations for CHEK.Check TMO's competition here
Danaher Corporation (NYSE: DHR)
CHEK vs DHR Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, DHR has a market cap of 161.9B. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while DHR trades at $230.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas DHR's P/E ratio is 28.86. In terms of profitability, CHEK's ROE is -2.26%, compared to DHR's ROE of +0.08%. Regarding short-term risk, CHEK is more volatile compared to DHR. This indicates higher risk in terms of short-term price fluctuations for CHEK.Check DHR's competition here
IDEXX Laboratories, Inc. (NASDAQ: IDXX)
CHEK vs IDXX Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, IDXX has a market cap of 53.3B. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while IDXX trades at $676.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas IDXX's P/E ratio is 47.54. In terms of profitability, CHEK's ROE is -2.26%, compared to IDXX's ROE of +0.71%. Regarding short-term risk, CHEK is more volatile compared to IDXX. This indicates higher risk in terms of short-term price fluctuations for CHEK.Check IDXX's competition here
Agilent Technologies, Inc. (NYSE: A)
CHEK vs A Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, A has a market cap of 49.3B. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while A trades at $174.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas A's P/E ratio is 30.08. In terms of profitability, CHEK's ROE is -2.26%, compared to A's ROE of +0.20%. Regarding short-term risk, CHEK is more volatile compared to A. This indicates higher risk in terms of short-term price fluctuations for CHEK.Check A's competition here
Waters Corporation (NYSE: WAT)
CHEK vs WAT Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, WAT has a market cap of 44.9B. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while WAT trades at $457.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas WAT's P/E ratio is 33.45. In terms of profitability, CHEK's ROE is -2.26%, compared to WAT's ROE of +0.01%. Regarding short-term risk, CHEK is more volatile compared to WAT. This indicates higher risk in terms of short-term price fluctuations for CHEK.Check WAT's competition here
IQVIA Holdings Inc. (NYSE: IQV)
CHEK vs IQV Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, IQV has a market cap of 44.8B. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while IQV trades at $271.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas IQV's P/E ratio is 22.40. In terms of profitability, CHEK's ROE is -2.26%, compared to IQV's ROE of +0.22%. Regarding short-term risk, CHEK is more volatile compared to IQV. This indicates higher risk in terms of short-term price fluctuations for CHEK.Check IQV's competition here
Natera, Inc. (NASDAQ: NTRA)
CHEK vs NTRA Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, NTRA has a market cap of 44.7B. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while NTRA trades at $310.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas NTRA's P/E ratio is -235.14. In terms of profitability, CHEK's ROE is -2.26%, compared to NTRA's ROE of -0.09%. Regarding short-term risk, CHEK is less volatile compared to NTRA. This indicates lower risk in terms of short-term price fluctuations for CHEK.Check NTRA's competition here
Mettler-Toledo International Inc. (NYSE: MTD)
CHEK vs MTD Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, MTD has a market cap of 34.5B. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while MTD trades at $1,722.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas MTD's P/E ratio is 39.56. In terms of profitability, CHEK's ROE is -2.26%, compared to MTD's ROE of +149.66%. Regarding short-term risk, CHEK is less volatile compared to MTD. This indicates lower risk in terms of short-term price fluctuations for CHEK.Check MTD's competition here
Illumina, Inc. (NASDAQ: ILMN)
CHEK vs ILMN Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, ILMN has a market cap of 32.2B. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while ILMN trades at $213.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas ILMN's P/E ratio is 42.36. In terms of profitability, CHEK's ROE is -2.26%, compared to ILMN's ROE of +0.31%. Regarding short-term risk, CHEK is less volatile compared to ILMN. This indicates lower risk in terms of short-term price fluctuations for CHEK.Check ILMN's competition here
Labcorp Holdings Inc. (NYSE: LH)
CHEK vs LH Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, LH has a market cap of 29.8B. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while LH trades at $366.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas LH's P/E ratio is 21.76. In terms of profitability, CHEK's ROE is -2.26%, compared to LH's ROE of +0.12%. Regarding short-term risk, CHEK is more volatile compared to LH. This indicates higher risk in terms of short-term price fluctuations for CHEK.Check LH's competition here
Quest Diagnostics Incorporated (NYSE: DGX)
CHEK vs DGX Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, DGX has a market cap of 28.2B. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while DGX trades at $255.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas DGX's P/E ratio is 25.22. In terms of profitability, CHEK's ROE is -2.26%, compared to DGX's ROE of +0.15%. Regarding short-term risk, CHEK is more volatile compared to DGX. This indicates higher risk in terms of short-term price fluctuations for CHEK.Check DGX's competition here
Guardant Health, Inc. (NASDAQ: GH)
CHEK vs GH Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, GH has a market cap of 20.3B. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while GH trades at $150.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas GH's P/E ratio is -43.33. In terms of profitability, CHEK's ROE is -2.26%, compared to GH's ROE of +2.49%. Regarding short-term risk, CHEK is less volatile compared to GH. This indicates lower risk in terms of short-term price fluctuations for CHEK.Check GH's competition here
Exact Sciences Corporation (NASDAQ: EXAS)
CHEK vs EXAS Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, EXAS has a market cap of 20B. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while EXAS trades at $104.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas EXAS's P/E ratio is -95.37. In terms of profitability, CHEK's ROE is -2.26%, compared to EXAS's ROE of -0.04%. Regarding short-term risk, CHEK is more volatile compared to EXAS. This indicates higher risk in terms of short-term price fluctuations for CHEK.Check EXAS's competition here
Medpace Holdings, Inc. (NASDAQ: MEDP)
CHEK vs MEDP Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, MEDP has a market cap of 18.3B. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while MEDP trades at $653.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas MEDP's P/E ratio is 36.22. In terms of profitability, CHEK's ROE is -2.26%, compared to MEDP's ROE of +1.00%. Regarding short-term risk, CHEK is more volatile compared to MEDP. This indicates higher risk in terms of short-term price fluctuations for CHEK.Check MEDP's competition here
Revvity, Inc. (NYSE: RVTY)
CHEK vs RVTY Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, RVTY has a market cap of 17.3B. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while RVTY trades at $155.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas RVTY's P/E ratio is 29.01. In terms of profitability, CHEK's ROE is -2.26%, compared to RVTY's ROE of +0.04%. Regarding short-term risk, CHEK is less volatile compared to RVTY. This indicates lower risk in terms of short-term price fluctuations for CHEK.Check RVTY's competition here
Illumina, Inc. Common Stock Ex-distribution When-Issued (NASDAQ: ILMNV)
CHEK vs ILMNV Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, ILMNV has a market cap of 17B. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while ILMNV trades at $107.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas ILMNV's P/E ratio is N/A. In terms of profitability, CHEK's ROE is -2.26%, compared to ILMNV's ROE of N/A. Regarding short-term risk, CHEK is more volatile compared to ILMNV. This indicates higher risk in terms of short-term price fluctuations for CHEK.Check ILMNV's competition here
Charles River Laboratories International, Inc. (NYSE: CRL)
CHEK vs CRL Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, CRL has a market cap of 16.2B. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while CRL trades at $337.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas CRL's P/E ratio is 34.09. In terms of profitability, CHEK's ROE is -2.26%, compared to CRL's ROE of +0.01%. Regarding short-term risk, CHEK is less volatile compared to CRL. This indicates lower risk in terms of short-term price fluctuations for CHEK.Check CRL's competition here
ICON Public Limited Company (NASDAQ: ICLR)
CHEK vs ICLR Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, ICLR has a market cap of 15.3B. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while ICLR trades at $204.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas ICLR's P/E ratio is 16.71. In terms of profitability, CHEK's ROE is -2.26%, compared to ICLR's ROE of +0.05%. Regarding short-term risk, CHEK is more volatile compared to ICLR. This indicates higher risk in terms of short-term price fluctuations for CHEK.Check ICLR's competition here
PerkinElmer, Inc. (NYSE: PKI)
CHEK vs PKI Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas PKI's P/E ratio is 41.45. In terms of profitability, CHEK's ROE is -2.26%, compared to PKI's ROE of +0.04%. Regarding short-term risk, CHEK is more volatile compared to PKI. This indicates higher risk in terms of short-term price fluctuations for CHEK.Check PKI's competition here
Qiagen N.V. (NYSE: QGEN)
CHEK vs QGEN Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, QGEN has a market cap of 10.4B. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while QGEN trades at $50.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas QGEN's P/E ratio is 20.79. In terms of profitability, CHEK's ROE is -2.26%, compared to QGEN's ROE of +0.12%. Regarding short-term risk, CHEK is more volatile compared to QGEN. This indicates higher risk in terms of short-term price fluctuations for CHEK.Check QGEN's competition here
RadNet, Inc. (NASDAQ: RDNT)
CHEK vs RDNT Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, RDNT has a market cap of 6B. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while RDNT trades at $76.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas RDNT's P/E ratio is 164.87. In terms of profitability, CHEK's ROE is -2.26%, compared to RDNT's ROE of -0.02%. Regarding short-term risk, CHEK is less volatile compared to RDNT. This indicates lower risk in terms of short-term price fluctuations for CHEK.Check RDNT's competition here
GRAIL Inc. (NASDAQ: GRAL)
CHEK vs GRAL Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, GRAL has a market cap of 5.4B. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while GRAL trades at $121.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas GRAL's P/E ratio is -12.45. In terms of profitability, CHEK's ROE is -2.26%, compared to GRAL's ROE of -0.16%. Regarding short-term risk, CHEK is less volatile compared to GRAL. This indicates lower risk in terms of short-term price fluctuations for CHEK.Check GRAL's competition here
BillionToOne, Inc. (NASDAQ: BLLN)
CHEK vs BLLN Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, BLLN has a market cap of 5.4B. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while BLLN trades at $113.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas BLLN's P/E ratio is 162.81. In terms of profitability, CHEK's ROE is -2.26%, compared to BLLN's ROE of +0.09%. Regarding short-term risk, CHEK is less volatile compared to BLLN. This indicates lower risk in terms of short-term price fluctuations for CHEK.Check BLLN's competition here
Sotera Health Company (NASDAQ: SHC)
CHEK vs SHC Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, SHC has a market cap of 4.6B. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while SHC trades at $16.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas SHC's P/E ratio is 16.68. In terms of profitability, CHEK's ROE is -2.26%, compared to SHC's ROE of +0.26%. Regarding short-term risk, CHEK is more volatile compared to SHC. This indicates higher risk in terms of short-term price fluctuations for CHEK.Check SHC's competition here
Syneos Health, Inc. (NASDAQ: SYNH)
CHEK vs SYNH Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas SYNH's P/E ratio is 61.40. In terms of profitability, CHEK's ROE is -2.26%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, CHEK is more volatile compared to SYNH. This indicates higher risk in terms of short-term price fluctuations for CHEK.Check SYNH's competition here
CareDx, Inc (NASDAQ: CDNA)
CHEK vs CDNA Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, CDNA has a market cap of 4.1B. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while CDNA trades at $78.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas CDNA's P/E ratio is 93.46. In terms of profitability, CHEK's ROE is -2.26%, compared to CDNA's ROE of +0.34%. Regarding short-term risk, CHEK is less volatile compared to CDNA. This indicates lower risk in terms of short-term price fluctuations for CHEK.Check CDNA's competition here
Olink Holding AB (publ) (NASDAQ: OLK)
CHEK vs OLK Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas OLK's P/E ratio is -96.59. In terms of profitability, CHEK's ROE is -2.26%, compared to OLK's ROE of -0.07%. Regarding short-term risk, CHEK is more volatile compared to OLK. This indicates higher risk in terms of short-term price fluctuations for CHEK.Check OLK's competition here
NeoGenomics, Inc. (NASDAQ: NEO)
CHEK vs NEO Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, NEO has a market cap of 2.2B. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while NEO trades at $16.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas NEO's P/E ratio is 129.54. In terms of profitability, CHEK's ROE is -2.26%, compared to NEO's ROE of -0.04%. Regarding short-term risk, CHEK is more volatile compared to NEO. This indicates higher risk in terms of short-term price fluctuations for CHEK.Check NEO's competition here
Veracyte, Inc. (NASDAQ: VCYT)
CHEK vs VCYT Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, VCYT has a market cap of 1.9B. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while VCYT trades at $24.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas VCYT's P/E ratio is 12.07. In terms of profitability, CHEK's ROE is -2.26%, compared to VCYT's ROE of +0.09%. Regarding short-term risk, CHEK is less volatile compared to VCYT. This indicates lower risk in terms of short-term price fluctuations for CHEK.Check VCYT's competition here
GeneDx Holdings Corp. (NASDAQ: WGS)
CHEK vs WGS Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, WGS has a market cap of 1.9B. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while WGS trades at $62.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas WGS's P/E ratio is 173.25. In terms of profitability, CHEK's ROE is -2.26%, compared to WGS's ROE of -0.39%. Regarding short-term risk, CHEK is less volatile compared to WGS. This indicates lower risk in terms of short-term price fluctuations for CHEK.Check WGS's competition here
Personalis, Inc. (NASDAQ: PSNL)
CHEK vs PSNL Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, PSNL has a market cap of 1.7B. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while PSNL trades at $15.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas PSNL's P/E ratio is -14.48. In terms of profitability, CHEK's ROE is -2.26%, compared to PSNL's ROE of -0.50%. Regarding short-term risk, CHEK is more volatile compared to PSNL. This indicates higher risk in terms of short-term price fluctuations for CHEK.Check PSNL's competition here
OPKO Health, Inc. (NASDAQ: OPK)
CHEK vs OPK Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, OPK has a market cap of 1.3B. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while OPK trades at $1.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas OPK's P/E ratio is -19.17. In terms of profitability, CHEK's ROE is -2.26%, compared to OPK's ROE of -0.12%. Regarding short-term risk, CHEK is less volatile compared to OPK. This indicates lower risk in terms of short-term price fluctuations for CHEK.Check OPK's competition here
Castle Biosciences, Inc. (NASDAQ: CSTL)
CHEK vs CSTL Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, CSTL has a market cap of 993.2M. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while CSTL trades at $32.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas CSTL's P/E ratio is -49.26. In terms of profitability, CHEK's ROE is -2.26%, compared to CSTL's ROE of -0.05%. Regarding short-term risk, CHEK is less volatile compared to CSTL. This indicates lower risk in terms of short-term price fluctuations for CHEK.Check CSTL's competition here
Fulgent Genetics, Inc. (NASDAQ: FLGT)
CHEK vs FLGT Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, FLGT has a market cap of 654.3M. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while FLGT trades at $23.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas FLGT's P/E ratio is 2378.00. In terms of profitability, CHEK's ROE is -2.26%, compared to FLGT's ROE of -0.09%. Regarding short-term risk, CHEK is less volatile compared to FLGT. This indicates lower risk in terms of short-term price fluctuations for CHEK.Check FLGT's competition here
GRAIL, Inc. Common Stock (NASDAQ: GRALV)
CHEK vs GRALV Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas GRALV's P/E ratio is N/A. In terms of profitability, CHEK's ROE is -2.26%, compared to GRALV's ROE of N/A. Regarding short-term risk, CHEK is less volatile compared to GRALV. This indicates lower risk in terms of short-term price fluctuations for CHEK.Check GRALV's competition here
Myriad Genetics, Inc. (NASDAQ: MYGN)
CHEK vs MYGN Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, MYGN has a market cap of 564.3M. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while MYGN trades at $5.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas MYGN's P/E ratio is -45.38. In terms of profitability, CHEK's ROE is -2.26%, compared to MYGN's ROE of -0.40%. Regarding short-term risk, CHEK is less volatile compared to MYGN. This indicates lower risk in terms of short-term price fluctuations for CHEK.Check MYGN's competition here
Global Cord Blood Corporation (NYSE: CO)
CHEK vs CO Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas CO's P/E ratio is 5.06. In terms of profitability, CHEK's ROE is -2.26%, compared to CO's ROE of +0.11%. Regarding short-term risk, CHEK is less volatile compared to CO. This indicates lower risk in terms of short-term price fluctuations for CHEK.Check CO's competition here
Standard BioTools Inc. (NASDAQ: FLDM)
CHEK vs FLDM Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas FLDM's P/E ratio is -4.74. In terms of profitability, CHEK's ROE is -2.26%, compared to FLDM's ROE of +0.26%. Regarding short-term risk, CHEK is less volatile compared to FLDM. This indicates lower risk in terms of short-term price fluctuations for CHEK.Check FLDM's competition here
Exagen Inc. (NASDAQ: XGN)
CHEK vs XGN Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, XGN has a market cap of 140.5M. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while XGN trades at $5.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas XGN's P/E ratio is -7.16. In terms of profitability, CHEK's ROE is -2.26%, compared to XGN's ROE of -1.22%. Regarding short-term risk, CHEK is less volatile compared to XGN. This indicates lower risk in terms of short-term price fluctuations for CHEK.Check XGN's competition here
Genetron Holdings Limited (NASDAQ: GTH)
CHEK vs GTH Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas GTH's P/E ratio is -1.11. In terms of profitability, CHEK's ROE is -2.26%, compared to GTH's ROE of -1.01%. Regarding short-term risk, CHEK is more volatile compared to GTH. This indicates higher risk in terms of short-term price fluctuations for CHEK.Check GTH's competition here
Genetic Technologies Limited (NASDAQ: GENE)
CHEK vs GENE Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas GENE's P/E ratio is -38.25. In terms of profitability, CHEK's ROE is -2.26%, compared to GENE's ROE of -1.85%. Regarding short-term risk, CHEK is more volatile compared to GENE. This indicates higher risk in terms of short-term price fluctuations for CHEK.Check GENE's competition here
Freenome, Inc. (NASDAQ: FRNM)
CHEK vs FRNM Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, FRNM has a market cap of 83M. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while FRNM trades at $10.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas FRNM's P/E ratio is N/A. In terms of profitability, CHEK's ROE is -2.26%, compared to FRNM's ROE of N/A. Regarding short-term risk, CHEK is less volatile compared to FRNM. This indicates lower risk in terms of short-term price fluctuations for CHEK.Check FRNM's competition here
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX)
CHEK vs IMDX Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, IMDX has a market cap of 81.5M. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while IMDX trades at $2.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas IMDX's P/E ratio is -1.67. In terms of profitability, CHEK's ROE is -2.26%, compared to IMDX's ROE of +2.72%. Regarding short-term risk, CHEK is less volatile compared to IMDX. This indicates lower risk in terms of short-term price fluctuations for CHEK.Check IMDX's competition here
Biodesix, Inc. (NASDAQ: BDSX)
CHEK vs BDSX Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, BDSX has a market cap of 69.8M. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while BDSX trades at $8.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas BDSX's P/E ratio is -2.71. In terms of profitability, CHEK's ROE is -2.26%, compared to BDSX's ROE of -4.42%. Regarding short-term risk, CHEK is less volatile compared to BDSX. This indicates lower risk in terms of short-term price fluctuations for CHEK.Check BDSX's competition here
Precipio, Inc. (NASDAQ: PRPO)
CHEK vs PRPO Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, PRPO has a market cap of 33.5M. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while PRPO trades at $18.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas PRPO's P/E ratio is -28.78. In terms of profitability, CHEK's ROE is -2.26%, compared to PRPO's ROE of -0.08%. Regarding short-term risk, CHEK is less volatile compared to PRPO. This indicates lower risk in terms of short-term price fluctuations for CHEK.Check PRPO's competition here
Akumin Inc. (NASDAQ: AKU)
CHEK vs AKU Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas AKU's P/E ratio is -0.13. In terms of profitability, CHEK's ROE is -2.26%, compared to AKU's ROE of -5.32%. Regarding short-term risk, CHEK is less volatile compared to AKU. This indicates lower risk in terms of short-term price fluctuations for CHEK.Check AKU's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAF)
CHEK vs BIAF Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, BIAF has a market cap of 17.3M. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while BIAF trades at $2.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas BIAF's P/E ratio is -0.32. In terms of profitability, CHEK's ROE is -2.26%, compared to BIAF's ROE of -2.57%. Regarding short-term risk, CHEK is less volatile compared to BIAF. This indicates lower risk in terms of short-term price fluctuations for CHEK.Check BIAF's competition here
Chembio Diagnostics, Inc. (NASDAQ: CEMI)
CHEK vs CEMI Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas CEMI's P/E ratio is -0.63. In terms of profitability, CHEK's ROE is -2.26%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, CHEK is more volatile compared to CEMI. This indicates higher risk in terms of short-term price fluctuations for CHEK.Check CEMI's competition here
Enzo Biochem, Inc. (NYSE: ENZ)
CHEK vs ENZ Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas ENZ's P/E ratio is -2.24. In terms of profitability, CHEK's ROE is -2.26%, compared to ENZ's ROE of -0.39%. Regarding short-term risk, CHEK is less volatile compared to ENZ. This indicates lower risk in terms of short-term price fluctuations for CHEK.Check ENZ's competition here
Quantum Cyber N.V. (NASDAQ: QUCY)
CHEK vs QUCY Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, QUCY has a market cap of 16.3M. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while QUCY trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas QUCY's P/E ratio is -0.03. In terms of profitability, CHEK's ROE is -2.26%, compared to QUCY's ROE of -3.65%. Regarding short-term risk, CHEK is less volatile compared to QUCY. This indicates lower risk in terms of short-term price fluctuations for CHEK.Check QUCY's competition here
Psychemedics Corporation (NASDAQ: PMD)
CHEK vs PMD Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, PMD has a market cap of 15.6M. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas PMD's P/E ratio is -5.24. In terms of profitability, CHEK's ROE is -2.26%, compared to PMD's ROE of -0.32%. Regarding short-term risk, CHEK is more volatile compared to PMD. This indicates higher risk in terms of short-term price fluctuations for CHEK.Check PMD's competition here
23andMe Holding Co. (NASDAQ: ME)
CHEK vs ME Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, ME has a market cap of 15.3M. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas ME's P/E ratio is -0.03. In terms of profitability, CHEK's ROE is -2.26%, compared to ME's ROE of -3.47%. Regarding short-term risk, CHEK is more volatile compared to ME. This indicates higher risk in terms of short-term price fluctuations for CHEK.Check ME's competition here
MDxHealth S.A. (NASDAQ: MDXH)
CHEK vs MDXH Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, MDXH has a market cap of 15.3M. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while MDXH trades at $0.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas MDXH's P/E ratio is -0.22. In terms of profitability, CHEK's ROE is -2.26%, compared to MDXH's ROE of +1.43%. Regarding short-term risk, CHEK is less volatile compared to MDXH. This indicates lower risk in terms of short-term price fluctuations for CHEK.Check MDXH's competition here
Mainz Biomed B.V. (NASDAQ: MYNZ)
CHEK vs MYNZ Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, MYNZ has a market cap of 14.7M. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while MYNZ trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas MYNZ's P/E ratio is -1.33. In terms of profitability, CHEK's ROE is -2.26%, compared to MYNZ's ROE of -1.80%. Regarding short-term risk, CHEK is less volatile compared to MYNZ. This indicates lower risk in terms of short-term price fluctuations for CHEK.Check MYNZ's competition here
Burning Rock Biotech Limited (NASDAQ: BNR)
CHEK vs BNR Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, BNR has a market cap of 14.5M. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while BNR trades at $13.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas BNR's P/E ratio is -15.79. In terms of profitability, CHEK's ROE is -2.26%, compared to BNR's ROE of -0.13%. Regarding short-term risk, CHEK is less volatile compared to BNR. This indicates lower risk in terms of short-term price fluctuations for CHEK.Check BNR's competition here
Centogene N.V. (NASDAQ: CNTG)
CHEK vs CNTG Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas CNTG's P/E ratio is -0.23. In terms of profitability, CHEK's ROE is -2.26%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, CHEK is more volatile compared to CNTG. This indicates higher risk in terms of short-term price fluctuations for CHEK.Check CNTG's competition here
Applied DNA Sciences, Inc. (NASDAQ: APDN)
CHEK vs APDN Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, APDN has a market cap of 7.3M. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while APDN trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas APDN's P/E ratio is -0.10. In terms of profitability, CHEK's ROE is -2.26%, compared to APDN's ROE of -7.23%. Regarding short-term risk, CHEK is less volatile compared to APDN. This indicates lower risk in terms of short-term price fluctuations for CHEK.Check APDN's competition here
ENDRA Life Sciences Inc. (NASDAQ: NDRA)
CHEK vs NDRA Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, NDRA has a market cap of 7.1M. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while NDRA trades at $4.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas NDRA's P/E ratio is -0.70. In terms of profitability, CHEK's ROE is -2.26%, compared to NDRA's ROE of -2.25%. Regarding short-term risk, CHEK is less volatile compared to NDRA. This indicates lower risk in terms of short-term price fluctuations for CHEK.Check NDRA's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAFW)
CHEK vs BIAFW Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, BIAFW has a market cap of 7M. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while BIAFW trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas BIAFW's P/E ratio is 0.75. In terms of profitability, CHEK's ROE is -2.26%, compared to BIAFW's ROE of -2.57%. Regarding short-term risk, CHEK is less volatile compared to BIAFW. This indicates lower risk in terms of short-term price fluctuations for CHEK.Check BIAFW's competition here
Invitae Corporation (NYSE: NVTA)
CHEK vs NVTA Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas NVTA's P/E ratio is -0.00. In terms of profitability, CHEK's ROE is -2.26%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, CHEK is less volatile compared to NVTA. This indicates lower risk in terms of short-term price fluctuations for CHEK.Check NVTA's competition here
LumiraDx Limited (NASDAQ: LMDX)
CHEK vs LMDX Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas LMDX's P/E ratio is -0.01. In terms of profitability, CHEK's ROE is -2.26%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, CHEK is less volatile compared to LMDX. This indicates lower risk in terms of short-term price fluctuations for CHEK.Check LMDX's competition here
LumiraDx Limited (NASDAQ: LMDXW)
CHEK vs LMDXW Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, CHEK's ROE is -2.26%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, CHEK is less volatile compared to LMDXW. This indicates lower risk in terms of short-term price fluctuations for CHEK.Check LMDXW's competition here
Advanced Biomed Inc. Common Stock (NASDAQ: ADVB)
CHEK vs ADVB Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, ADVB has a market cap of 3.3M. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while ADVB trades at $1.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas ADVB's P/E ratio is -18.32. In terms of profitability, CHEK's ROE is -2.26%, compared to ADVB's ROE of +1.22%. Regarding short-term risk, CHEK is less volatile compared to ADVB. This indicates lower risk in terms of short-term price fluctuations for CHEK.Check ADVB's competition here
DermTech, Inc. (NASDAQ: DMTK)
CHEK vs DMTK Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas DMTK's P/E ratio is -0.04. In terms of profitability, CHEK's ROE is -2.26%, compared to DMTK's ROE of -1.06%. Regarding short-term risk, CHEK is less volatile compared to DMTK. This indicates lower risk in terms of short-term price fluctuations for CHEK.Check DMTK's competition here
Inotiv, Inc. (NASDAQ: NOTV)
CHEK vs NOTV Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, NOTV has a market cap of 2.8M. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while NOTV trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas NOTV's P/E ratio is -0.03. In terms of profitability, CHEK's ROE is -2.26%, compared to NOTV's ROE of -0.75%. Regarding short-term risk, CHEK is less volatile compared to NOTV. This indicates lower risk in terms of short-term price fluctuations for CHEK.Check NOTV's competition here
SeqLL Inc. (NASDAQ: SQL)
CHEK vs SQL Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas SQL's P/E ratio is -0.40. In terms of profitability, CHEK's ROE is -2.26%, compared to SQL's ROE of -30.46%. Regarding short-term risk, CHEK is less volatile compared to SQL. This indicates lower risk in terms of short-term price fluctuations for CHEK.Check SQL's competition here
Aspira Women's Health Inc. (NASDAQ: AWH)
CHEK vs AWH Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, AWH has a market cap of 2.5M. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas AWH's P/E ratio is -0.09. In terms of profitability, CHEK's ROE is -2.26%, compared to AWH's ROE of +1.62%. Regarding short-term risk, CHEK is more volatile compared to AWH. This indicates higher risk in terms of short-term price fluctuations for CHEK.Check AWH's competition here
iSpecimen Inc. (NASDAQ: ISPC)
CHEK vs ISPC Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, ISPC has a market cap of 2M. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while ISPC trades at $0.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas ISPC's P/E ratio is -0.03. In terms of profitability, CHEK's ROE is -2.26%, compared to ISPC's ROE of -5.24%. Regarding short-term risk, CHEK is less volatile compared to ISPC. This indicates lower risk in terms of short-term price fluctuations for CHEK.Check ISPC's competition here
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM)
CHEK vs HTGM Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas HTGM's P/E ratio is -0.03. In terms of profitability, CHEK's ROE is -2.26%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, CHEK is more volatile compared to HTGM. This indicates higher risk in terms of short-term price fluctuations for CHEK.Check HTGM's competition here
Biocept, Inc. (NASDAQ: BIOC)
CHEK vs BIOC Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas BIOC's P/E ratio is -0.01. In terms of profitability, CHEK's ROE is -2.26%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, CHEK is less volatile compared to BIOC. This indicates lower risk in terms of short-term price fluctuations for CHEK.Check BIOC's competition here
SeqLL Inc. (NASDAQ: SQLLW)
CHEK vs SQLLW Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, SQLLW has a market cap of 179.6K. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas SQLLW's P/E ratio is -0.00. In terms of profitability, CHEK's ROE is -2.26%, compared to SQLLW's ROE of -30.46%. Regarding short-term risk, CHEK is less volatile compared to SQLLW. This indicates lower risk in terms of short-term price fluctuations for CHEK.Check SQLLW's competition here
GeneDx Holdings Corp. (NASDAQ: WGSWW)
CHEK vs WGSWW Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, WGSWW has a market cap of 5.8K. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while WGSWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas WGSWW's P/E ratio is -0.00. In terms of profitability, CHEK's ROE is -2.26%, compared to WGSWW's ROE of -0.39%. Regarding short-term risk, CHEK is more volatile compared to WGSWW. This indicates higher risk in terms of short-term price fluctuations for CHEK.Check WGSWW's competition here
BioNano Genomics, Inc. WT EXP 082123 (NASDAQ: BNGOW)
CHEK vs BNGOW Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, BNGOW has a market cap of 0. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while BNGOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas BNGOW's P/E ratio is N/A. In terms of profitability, CHEK's ROE is -2.26%, compared to BNGOW's ROE of -0.79%. Regarding short-term risk, CHEK is less volatile compared to BNGOW. This indicates lower risk in terms of short-term price fluctuations for CHEK.Check BNGOW's competition here
Check-Cap Ltd (NASDAQ: CHEKZ)
CHEK vs CHEKZ Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, CHEKZ has a market cap of 0. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while CHEKZ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas CHEKZ's P/E ratio is N/A. In terms of profitability, CHEK's ROE is -2.26%, compared to CHEKZ's ROE of +4.17%. Regarding short-term risk, CHEK is less volatile compared to CHEKZ. This indicates lower risk in terms of short-term price fluctuations for CHEK.Check CHEKZ's competition here
Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX)
CHEK vs OCDX Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, OCDX has a market cap of 0. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas OCDX's P/E ratio is -42.28. In terms of profitability, CHEK's ROE is -2.26%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, CHEK is more volatile compared to OCDX. This indicates higher risk in terms of short-term price fluctuations for CHEK.Check OCDX's competition here
Danaher Corporation (NYSE: DHR-PA)
CHEK vs DHR-PA Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, CHEK's ROE is -2.26%, compared to DHR-PA's ROE of +0.08%. Regarding short-term risk, CHEK is more volatile compared to DHR-PA. This indicates higher risk in terms of short-term price fluctuations for CHEK.Check DHR-PA's competition here
PAREXEL Intl Corp. (NASDAQ: PRXL)
CHEK vs PRXL Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, PRXL has a market cap of 0. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while PRXL trades at $88.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas PRXL's P/E ratio is 42.97. In terms of profitability, CHEK's ROE is -2.26%, compared to PRXL's ROE of +0.17%. Regarding short-term risk, CHEK is more volatile compared to PRXL. This indicates higher risk in terms of short-term price fluctuations for CHEK.Check PRXL's competition here
23andMe Holding Co. (NASDAQ: MEUSW)
CHEK vs MEUSW Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas MEUSW's P/E ratio is N/A. In terms of profitability, CHEK's ROE is -2.26%, compared to MEUSW's ROE of -3.47%. Regarding short-term risk, CHEK is less volatile compared to MEUSW. This indicates lower risk in terms of short-term price fluctuations for CHEK.Check MEUSW's competition here
ENDRA Life Sciences Inc. Warrants (NASDAQ: NDRAW)
CHEK vs NDRAW Comparison November 2026
Check-Cap Ltd. (NASDAQ: CHEK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHEK stands at 10.9M. In comparison, NDRAW has a market cap of 0. Regarding current trading prices, CHEK is priced at $1.86 on the NASDAQ, while NDRAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHEK currently has a P/E ratio of -0.43, whereas NDRAW's P/E ratio is N/A. In terms of profitability, CHEK's ROE is -2.26%, compared to NDRAW's ROE of -2.25%. Regarding short-term risk, CHEK is less volatile compared to NDRAW. This indicates lower risk in terms of short-term price fluctuations for CHEK.Check NDRAW's competition here